Work

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2560

Authors: Judy Sing-Zan Wang, Minal A. Barve, E. Gabriela Chiorean, Patricia LoRusso, Kevin Dale Courtney, Dan Qi, Arturo Olguin, John Bullington, Megan Sardone, Vanessa Dunn, Shay Shemesh, Janice Chen, Christopher Brooks, Todd Michael Bauer

Institutions: Florida Cancer Specialists & Research Institute, Mary Crowley Cancer Research Center, Fred Hutch Cancer Center, Yale Cancer Center, Yale University, The University of Texas Southwestern Medical Center, Stemline Therapeutics (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Nuclear Structure and Function

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891407387

Cites:

Cited by: 2

Related to: 10